Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
83.53USD
15 Feb 2019
83.53USD
15 Feb 2019
Change (% chg)
$0.50 (+0.60%)
$0.50 (+0.60%)
Prev Close
$83.03
$83.03
Open
$83.34
$83.34
Day's High
$83.65
$83.65
Day's Low
$82.19
$82.19
Volume
222,684
222,684
Avg. Vol
323,415
323,415
52-wk High
$153.80
$153.80
52-wk Low
$60.28
$60.28
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Dec '18 | 21.03 | -2.092 |
| Sep '18 | 2.07 | -2.434 | |
| Jun '18 | 29.91 | -1.627 | |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 13 | 23.08 | 50.25 | 13.90 | 90.76 |
| Quarter Ending Jun-19 | 13 | 30.75 | 80.71 | 18.00 | 131.94 |
| Year Ending Dec-19 | 18 | 158.73 | 396.08 | 91.19 | 455.30 |
| Year Ending Dec-20 | 18 | 411.11 | 874.74 | 253.00 | 956.79 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 14 | -2.14 | -1.62 | -2.49 | -1.47 |
| Quarter Ending Jun-19 | 14 | -2.17 | -1.76 | -2.52 | -1.27 |
| Year Ending Dec-19 | 16 | -8.73 | -7.24 | -9.85 | -4.43 |
| Year Ending Dec-20 | 15 | -6.95 | -3.72 | -8.55 | -0.77 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 69.44 | 33.70 | |
| P/E High - Last 5 Yrs. | -- | 147.79 | 49.87 | |
| P/E Low - Last 5 Yrs. | -- | 47.97 | 24.25 | |
| Beta | 2.97 | 1.08 | 0.90 | |
| Price to Sales (TTM) | 170.48 | 49.51 | 6.29 | |
| Price to Book (MRQ) | 10.02 | 10.14 | 5.26 | |
| Price to Tangible Book (MRQ) | 10.02 | 13.78 | 6.77 | |
| Price to Cash Flow (TTM) | -- | 56.20 | 24.98 | |
| % Owned Institutions | 96.38 | 3.74 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.12 | 1.40 | |
| Dividend Yield - 5 Year Avg | -- | 0.09 | 1.42 | |
| Dividend 5 Year Growth Rate | -- | 0.79 | 4.85 | |
| Payout Ratio(TTM) | -- | 7.02 | 41.03 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 205.92 | 12.75 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 48.79 | 5.84 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 22.76 | 11.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 75.85 | 47.15 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 11.98 | 10.85 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 9.07 | 15.20 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.24 | 2.25 |
| Current Ratio (MRQ) | 8.84 | 3.50 | 3.08 |
| LT Debt to Equity (MRQ) | 13.36 | 18.65 | 11.38 |
| Total Debt to Equity (MRQ) | 13.36 | 31.33 | 16.12 |
| Interest Coverage (TTM) | -- | -43.11 | 29.47 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 56.24 | 53.81 | |
| Gross Margin - 5 Yr. Avg. | -- | 60.48 | 52.18 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -110.45 | 12.86 | |
| Operating Margin (TTM) | -680.48 | -184.67 | 6.20 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -126.94 | 8.31 | |
| Pre-Tax Margin (TTM) | -670.81 | -175.36 | 7.16 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -132.73 | 8.61 | |
| Net Profit Margin (TTM) | -670.81 | -182.07 | 3.29 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -137.12 | 4.89 | |
| Effective Tax Rate (TTM) | -- | 22.48 | 22.91 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 15.51 | 23.38 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 7,654,354 | 842,397,297 | |
| Net Income/Employee (TTM) | -861,313 | 562,076 | 99,842,671 | |
| Receivable Turnover (TTM) | 5.30 | 6.23 | 5.71 | |
| Inventory Turnover (TTM) | -- | 1.89 | 3.47 | |
| Asset Turnover (TTM) | 0.05 | 0.32 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | 6.39 | 11.06 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | 5.47 | 12.20 | |
| Return on Investment (TTM) | -33.58 | 8.92 | 14.45 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 6.78 | 15.87 | |
| Return on Equity (TTM) | -39.86 | 10.08 | 15.96 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 8.32 | 17.00 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 99 |
| 13 Week | 45.87 | 38.77 | 99 | 95 |
| 26 Week | 152.83 | 133.61 | 99 | 98 |
| 52 Week | 238.72 | 187.09 | 99 | 72 |
| YTD | 227.59 | 187.69 | 99 | 72 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Eli Lilly makes bet on gene-silencing drug firm Dicerna
- UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- With Hemlibra, Roche seeks to break into tight hemophilia circle
- With Hemlibra, Roche seeks to break into tight hemophilia circle
Institutional Holders
| % Shares Owned: | 88.46% |
| # of Holders: | 435 |
| Total Shares Held: | 93,923,340 |
| 3 Mo. Net Change: | 2,439,774 |
| # New Positions: | 31 |
| # Closed Positions: | 55 |
| # Increased Positions: | 174 |
| # Reduced Positions: | 182 |
| # Net Buyers: | -8 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.